Abstract:Objective To evaluate the value of S100B gene on cardiovascular remodeling in rats with abdominal aorta coarctation.Method Sprague-Dawley rats(sanitary degree,male),weighring(220～240)g,were used in the study.They were provided by College of Medicine,Zhejiang University.The abdominal aortas of rats were isolated and constricted so as to establish models of heart failure;the abdominal aortas of another ten rats were isolated but not ligated(sham-operation group).After one week,the 20 rats were alive and randomly divided into 2 groups:operation group(n=10)and Carvidilol-operation group(Car group,n=10).Car Group was treatedwith 2 mg·kg-1per day Carvedilol and operation group was administered with the same doses of normal saline.After 4 weeks,a catheter was inserted through the right jngular artery into the left ventricle to record hemodynamic.Then all rats were euthanized,and the heart tissues were rapidly excised,rinsed with PBS.The left ventricles were then cut into two parts at the equator:the upper sections were fixation,the lower sections were stoted at-80℃,at 100 mg per tube.LV transverse section(4μm thick)was subjected to S100B immunehistoc- hemistry.RNA was iselated from tissues by Trlzol to determine levels of S100BmRNA and β-actinmRNA by RT- PCR.The data was expressed as(x±s);One-way analysis of variance was used for comparison among groups, and Student-Newman-Keulsa test for comparison between two groups.Statistical significance was set at P＜0.05. Results In Operation Group,there was a decrease in maximal rate of systolic and diastolic of left ventricular pressure(±dp/dtmax)[(1543.6±277.9)mmHg/s vs.(2640.4±481.3)mmHg/s and(-1352.5±202.3) mmHg/s vs.(-1873.2±412.3)mmHg/s];and an increase in left ventricular end diastolic pressure(LVEDP) [(24.8±5.2)mmHg vs.(2.1±0.7)mmHg]compared with sham-operation group(P＜0.01,P＜0.01 and P＜0.05).And in Car group,the level of LVEDP was just in the midst of the Operation Group and sham-opera- tion group,and had statistical significance(P＜0.01);while±dp/dtmac[(2372.3±92.6)mmHg/s and (-1786.4±62.6)mmHg/s]were much higher than those in operation group(P＜0.01).There were no any S100B positive cells and expression of S100B mRNA in sham-operation group;while there were much more S100B positive cells in operation group than those in Car group(P＜0.01).The expression of S100B mRNA in operation group was more pronounced than that in Car group.Changes in expression of S100BmRNA were positively correlat- ed with changes in LVEDP(r=0.847,P＜0.01);while changes in expression of S100BmRNA were negatively correlated with changes in±dp/dt max(r=-0.853 and-0.689,beth P＜0.01).Conclusions There was hish expression of S100B in myocytes from rats with experimental heart failure and negative correlation between the expression of S100B and heart function.It indicated that S100B could play a negative role in heart failure.

S100a8/9 (S100 Calcium Binding Protein a8/9) Promotes Cardiac Hypertrophy Via Upregulation of FGF23 (Fibroblast Growth Factor 23) in Mice

Cardiac-specific Overexpression of Farnesyl Pyrophosphate Synthase Induces Cardiac Hypertrophy and Dysfunction in Mice.

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

Targeting S100A9 Prevents β-Adrenergic Activation–Induced Cardiac Injury

Downregulation of S100A4 Alleviates Cardiac Fibrosis Via Wnt/β -Catenin Pathway in Mice.

Expression of S100B during heart failure in rats

S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-Induced cardiac inflammation and injury

S100A9 Promotes Human Lung Fibroblast Cells Activation Through Receptor for Advanced Glycation End-Product-mediated Extracellular-Regulated Kinase 1/2, Mitogen-Activated Protein-Kinase and Nuclear Factor-Κb-dependent Pathways

Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23

S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner

Abstract 13694: Hsf1 Attenuates Pressure Overload Induced-cardiac Fibrosis via Inhibiting Smad3 Phosphorylation and Nuclear Translocation

Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice

Advances in the study of S100A9 in cardiovascular diseases

Stem Cell Antigen 1 Protects Against Cardiac Hypertrophy And Fibrosis After Pressure Overload

Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca2+-ATPase Expression in Cardiomyocytes

S-nitrosylation of Hsp90 promotes cardiac hypertrophy in mice through GSK3β signaling

Effect of S100A9 on human lung fibroblast proliferation and activity

IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling

Crosstalk between FGF23- and angiotensin II-mediated Ca2+ signaling in pathological cardiac hypertrophy

Zinc Finger Protein 91 Loss Induces Cardiac Hypertrophy Through Adenosine A1 Receptor Down‐regulation under Pressure Overload Status

Unraveling the Mechanisms of S100A8/A9 in Myocardial Injury and Dysfunction